Allergan expanded its pipeline with a $50 million deal to bring in a late-stage treatment for dry eye as the company works to reaffirm its commitment to R&D in the face of industrywide scrutiny.
Cue the Medtronic-Covidien layoffs. Medtronic is cutting 150 jobs in Ireland, months after closing its megadeal with Covidien and shifting its domicile to the country to enjoy the benefits of a lower tax rate.
After Sanofi's sizable investment into its dengue vaccine program, new company CEO Olivier Brandicourt said on the Q3 call that the French pharma expects its first license to market the vaccine by year end.
Seeking to throw support into a field that has seen recent scientific advancements, the European Commission is stepping up with funding to form the European AIDS Vaccine Initiative. The effort will set out to develop protective and therapeutic HIV vaccines by bringing together experts from 22 institutions, both public and private.
GlaxoSmithKline has struck a deal to trial its anti-OX40 monoclonal antibody in combination with Merck's Keytruda. The Phase I study is part of a slate of programs that GSK is hoping will support filings for up to 20 new drug approvals in the coming years, the success rate of which will go a long way to deciding whether the company can bounce back from its recent travails.
Cardiac arrhythmia is the result of a specific kind of cell's presence in the heart that causes the organ to beat irregularly. And researchers from the University of Michigan have developed a nanoparticle that can target and destroy those cells without doing harm to the healthy cells in the heart.
Sanofi is pairing up with Germany's BioNTech in a collaboration potentially worth $1.5 billion, licensing some early-stage cancer immunotherapies that use messenger RNA to target tumors.
As scientists target gastrointestinal tract procedures as a way to treat Type 2 diabetes, Fractyl Labs is forging ahead with its balloon ablation device for the disease to cash in on the trend.
Infusion pump maker Flowonix Medical has been working hard this past year to beef up development for its drug delivery device, raising new funds and partnering with biotech Cebebral Therapeutics to broaden the reach for its technology. In its latest move, Flowonix has revealed the first implant of its drug delivery infusion pump in Connecticut.
Boehringer Ingelheim has expanded its crowdsourced R&D program into the field of psychiatric diseases, broadening its partnership with Germany's BioMed X to spotlight new therapies.